State Contract Pharmacy Lawsuit Weekly Roundup: AbbVie Asks 5th Circuit to Reverse Ruling, New Developments in Missouri and Kansas 

Key filings and orders occurred in lawsuits challenging the 340B contract pharmacy access law in Missouri.
Editor’s Note: With 340B-related litigation heating up in several states following the enactment of new contract pharmacy access laws, 340B [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

Breaking News

HHS to J&J: End 340B Rebate Proposal Immediately or ‘Face Potential Consequences’—Including Termination from Federal Health Insurance Programs

HHS sent J&J a Sept. 17 letter demanding the drugmaker "immediately" cease its plan to implement a 340B rebate model.
The federal agency that oversees the 340B program today formally warned Johnson & Johnson (J&J) that it must “cease implementation [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

Sen. Welch Hopes His Contract Pharmacy Bill Will Move Soon, ASAP 340B and PhRMA Push for Broader Bill

The Senate version of the 340B PATIENTS Act faces hurdles to passage despite broad support from provider groups.
The sponsor of new Senate legislation that would codify providers’ ability to use contract pharmacies to dispense 340B discounted drugs [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

Fourth Hospital Sues HRSA for Alleged ‘Unlawful’ Authorization of J&J 340B Program Audits

Children’s National Medical Center sued HRSA for approving a drugmaker's 340B audit request.
A Washington, D.C.-based children’s hospital has sued the federal government for authorizing drugmaker Johnson & Johnson (J&J) to perform “unlawful” [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

Diabetes Drugmakers Urge Federal Appeals Court to Dismiss Health Centers’ 340B Antitrust Lawsuit

Sanofi and three other diabetes drugmakers are urging a federal district court to dismiss 340B antitrust allegations against them.
Four diabetes drugmakers are urging a federal appeals court to uphold a lower court’s decision to dismiss 340B antitrust claims [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

Eli Lilly and Amgen Announce Refunds, Amgen Issues NDC Change

Eli Lilly and Amgen announced refunds for 340B covered entities that purchased certain drugs in 2021.
Two drugmakers recently announced that they will refund 340B covered entities that purchased certain medications following adjustments to their ceiling [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

News Alert

340B Covered Entities Threaten Action Against Drugmakers Over New Reporting Requirements

Second Sight Solutions updated 340B ESP's terms of use on Oct. 4.
A law firm representing hospitals and other 340B covered entities across the U.S. has called on more than two dozen [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

HHS Concessions in Contract Pharmacy Lawsuits Unlikely to Signal Shift in 340B Rebate Stance, Attorneys Say

The federal government is moving to resolve four contract pharmacy lawsuits, but may continue fighting Kalderos' 340B rebate model in court.
The federal government is likely to continue opposing 340B rebate models even as it moves to resolve four separate contract [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

State Contract Pharmacy Lawsuit Weekly Roundup: 5th Circuit Appeals and Updates in Arkansas, Minnesota, West Virginia

Key filings and orders occurred in lawsuits challenging the 340B contract pharmacy access law in Missouri.
Editor’s Note: With 340B-related litigation heating up in several states following the enactment of new contract pharmacy access laws, 340B [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

AstraZeneca Tightens Contract Pharmacy Restrictions to Require Claims Data Submission

AstraZeneca headquarters
AstraZeneca will discontinue a certain bottle dosage of its breast cancer drug Truqap (capiversatib) by the end of the year but allow 340B covered entities to replenish their supply with an equivalent dose in blister pack package form.
Beginning Oct. 1, AstraZeneca will tighten its 340B contract pharmacy restrictions to require claims data on 340B utilization at contract [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

*Sign up for news summaries and alerts from 340B Report

Site Footer Live